Latest Period
Q1 2026
Security Snapshot
Arcadia Biosciences, Inc. - Common (RKDA) Institutional Ownership
CUSIP: 039014204
13F Institutional Holders and Ownership History from Q4 2017 to Q1 2026
Institutions Reporting
1
Shares (Excl. Options)
1
Price
$1.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common
- Symbol
- RKDA on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 1
- Total 13F value
- $1
- Portfolio coverage rank
- 0%
- Share change
- +1
- Value change
- +$1
- Number of holders
- 1
- Shares outstanding
- 2,056,645
- SEC-reported price per share
- $1.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RKDA - Arcadia Biosciences, Inc. - Common is tracked under CUSIP 039014204.
- 1 institution reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 0 to 1 between Q1 2023 and Q1 2026.
- SEC-reported value moved from $0 to $1.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q1 2026.
Security key
039014204
Latest holder period
Q1 2026
13F holders
1
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
RKDA full holder history
Arcadia Biosciences, Inc. SEC filings
Arcadia Biosciences, Inc. company facts
Arcadia Biosciences, Inc. insider transactions
Arcadia Biosciences, Inc. 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 039014204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
RKDA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 7.8% | 159,390 | Armistice Capital, LLC | 31 Mar 2026 | ||||
| SABBY MANAGEMENT, LLC | 4.9% | $17,028 | 68,111 | SABBY MANAGEMENT, LLC | 31 Dec 2024 |
As of 31 Mar 2026, 1 institutional investors reported holding 1 shares of Arcadia Biosciences, Inc. - Common (RKDA). This represents 0% of the company’s total 2,056,645 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q1 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1 | $1 | +$1 | $1.00 | 1 |
| 2023 Q1 | 0 | $0 | -$639,500 | $1.00 | 0 |
| 2022 Q4 | 2,366,535 | $639,500 | -$254,174 | $0.27 | 26 |
| 2022 Q3 | 3,279,360 | $1,729,000 | +$775,233 | $0.53 | 20 |
| 2022 Q2 | 1,706,820 | $1,707,136 | -$245,035 | $1.00 | 19 |
| 2022 Q1 | 1,918,328 | $2,684,000 | -$453,395 | $1.40 | 23 |
| 2021 Q4 | 2,337,881 | $2,428,000 | -$2,445,760 | $1.04 | 24 |
| 2021 Q3 | 3,161,441 | $6,543,000 | +$1,274,798 | $2.07 | 18 |
| 2021 Q2 | 2,492,120 | $7,400,000 | +$4,101,343 | $2.97 | 24 |
| 2021 Q1 | 1,150,714 | $3,170,000 | +$191,545 | $2.75 | 22 |
| 2020 Q4 | 1,116,093 | $2,823,000 | +$624,930 | $2.53 | 17 |
| 2020 Q3 | 869,117 | $2,435,000 | +$932,821 | $2.80 | 18 |
| 2020 Q2 | 523,085 | $1,969,000 | +$371,528 | $3.77 | 14 |
| 2020 Q1 | 427,264 | $1,218,000 | -$643,194 | $2.86 | 11 |
| 2019 Q4 | 496,981 | $2,722,000 | -$790,872 | $5.48 | 13 |
| 2019 Q3 | 662,670 | $3,101,000 | +$1,149,076 | $4.68 | 17 |
| 2019 Q2 | 479,719 | $1,471,000 | +$709,694 | $3.07 | 13 |
| 2019 Q1 | 192,623 | $1,350,000 | +$38,014 | $7.01 | 10 |
| 2018 Q4 | 282,070 | $894,000 | -$561,407 | $3.17 | 10 |
| 2018 Q3 | 438,889 | $2,144,000 | -$22,395 | $4.88 | 12 |
| 2018 Q2 | 342,140 | $2,822,000 | -$4,604,714 | $8.25 | 11 |
| 2018 Q1 | 395,430 | $10,023,000 | +$10,016,000 | $24.01 | 11 |
| 2017 Q4 | 26,228 | $7,000 | +$7,000 | $0.27 | 1 |